STRO-002-GM1, a first in human, phase 1 study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC), including fallopian tube or primary peritoneal cancers

This article has no abstract
Epistemonikos ID: c523d7d5abb0bd7bdc890f599774579c96d973e8
First added on: Feb 12, 2025